TipRanks
Advertisement
Advertisement
Biosplice Therapeutics Submits NDA for First-in-Class Knee Osteoarthritis Drug Lorecivivint
PremiumPrivate CompaniesBiosplice Therapeutics Submits NDA for First-in-Class Knee Osteoarthritis Drug Lorecivivint
9M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―